CoChat

Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases

Open access
Graßhoff, Hanna, Comdühr, Sara, Monne, Luisa R., Müller, Antje, Lamprecht, Peter, Riemekasten, Gabriela, Humrich, Jens Y. · 2021 · Frontiers in Immunology
Cited by 167

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Regulatory T cells (Treg) are crucial for the maintenance of peripheral tolerance and for the control of ongoing inflammation and autoimmunity. The cytokine interleukin-2 (IL-2) is essentially required for the growth and survival of Treg in the peripheral lymphatic tissues and thus plays a vital role in the biology of Treg. Most autoimmune and rheumatic diseases exhibit disturbances in Treg biology either at a numerical or functional level resulting in an imbalance between protective and pathogenic immune cells. In addition, in some autoimmune diseases, a relative deficiency of IL-2 develops during disease pathogenesis leading to a disturbance of Treg homeostasis, which further amplifies the vicious cycle of tolerance breach and chronic inflammation. Low-dose IL-2 therapy aims either to compensate for this IL-2 deficiency to restore a physiological state or to strengthen the Treg population in order to be more effective in counter-regulating inflammation while avoiding global immunosuppression. Here we highlight key findings and summarize recent advances in the clinical translation of low-dose IL-2 therapy for the treatment of autoimmune and rheumatic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2021.648408

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 167

Metadata

Authors
Graßhoff, H., Comdühr, S., Monne, L. R., Müller, A., Lamprecht, P., Riemekasten, G., & Humrich, J. Y.
Venue
Frontiers in Immunology
Published
2021-04-01
Volume
12
Pages
648408-648408
ISSN
1664-3224 (ISSN-L)
OpenAlex
W3142178656
Cited by
167
References
7
FWCI
7.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. https://app.cochat.ai/papers/10.3389/fimmu.2021.648408
The paper
Graßhoff, H., Comdühr, S., Monne, L. R., Müller, A., Lamprecht, P., Riemekasten, G., & Humrich, J. Y. (2021). Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.648408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.